0000899243-17-024251.txt : 20171016 0000899243-17-024251.hdr.sgml : 20171016 20171016170737 ACCESSION NUMBER: 0000899243-17-024251 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20171013 FILED AS OF DATE: 20171016 DATE AS OF CHANGE: 20171016 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Xie Lan CENTRAL INDEX KEY: 0001555794 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-19825 FILM NUMBER: 171139313 MAIL ADDRESS: STREET 1: 29F SHANGHAI TIMES SQUARE STREET 2: NO. 93 HUAI HAI ZHONG ROAD CITY: SHANGHAI STATE: F4 ZIP: 200021 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: SCICLONE PHARMACEUTICALS INC CENTRAL INDEX KEY: 0000880771 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 943116852 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 950 TOWER LANE STREET 2: SUITE 900 CITY: FOSTER CITY STATE: CA ZIP: 94404-2125 BUSINESS PHONE: 650-358-3456 MAIL ADDRESS: STREET 1: 950 TOWER LANE STREET 2: SUITE 900 CITY: FOSTER CITY STATE: CA ZIP: 94404-2125 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2017-10-13 1 0000880771 SCICLONE PHARMACEUTICALS INC SCLN 0001555794 Xie Lan 950 TOWER LANE, SUITE 900 FOSTER CITY CA 94404 0 1 0 0 VP Finance, China CFO Common Stock 2017-10-13 4 M 0 8000 A 8000 D Common Stock 2017-10-13 4 D 0 8000 11.18 D 0 D Non-Qualified Stock Option (right to buy) 4.53 2017-10-13 4 D 0 2500 6.65 D 2023-04-04 Common Stock 2500 0 D Non-Qualified Stock Option (right to buy) 4.52 2017-10-13 4 D 0 16667 6.66 D 2024-03-14 Common Stock 16667 0 D Non-Qualified Stock Option (right to buy) 8.83 2017-10-13 4 D 0 18667 2.35 D 2025-03-16 Common Stock 18667 0 D Restricted Stock Unit 2017-10-13 4 M 0 2000 D Common Stock 2000 0 D Non-Qualified Stock Option (right to buy) 9.12 2017-10-13 4 D 0 28000 2.06 D 2026-03-15 Common Stock 28000 0 D Restricted Stock Unit 2017-10-13 4 M 0 3000 D Common Stock 3000 0 D Restricted Stock Unit 2017-10-13 4 M 0 3000 D Common Stock 3000 0 D Non-Qualified Stock Option (right to buy) 9.65 2017-10-13 4 D 0 21000 1.53 D 2027-03-08 Common Stock 21000 0 D Each restricted stock unit represented a contingent right to receive one share of SCLN common stock upon settlement. Granted under Issuer's 2005 Equity Incentive Plan. Under its terms the option became exercisable in installments with 25% vesting on April 4, 2014 and 2.0833% vesting each month thereafter until it became vested in full on April 4, 2017. The option was canceled immediately prior to the merger of Issuer and Silver Delaware Investment Limited (the "Merger") in exchange for a cash payment per share from the Issuer in an amount equal to the excess of $11.18 per share over the exercise price. Under its terms the option became exercisable in installments with 25% vesting on March 14, 2015 and 2.0833% vesting each month thereafter until it became vested in full immediately prior to the Merger. Under its terms the option became exercisable in installments with 25% vesting on March 16, 2016 and 2.0833% vesting each month thereafter until it became vested in full immediately prior to the Merger. Restricted stock units became fully vested and entitled to settlement immediately prior to the Merger and terminated upon settlement in shares of SCLN common stock. Granted under Issuer's 2015 Equity Incentive Plan. Under its terms the option became exercisable in installments with 25% vesting on March 15, 2017 and 2.0833% vesting each month thereafter until it became vested in full immediately prior to the Merger. Under its terms the option became exercisable in installments with 25% vesting on March 8, 2018 and 2.0833% vesting each month thereafter until it became vested in full immediately prior to the Merger. /s/ Friedhelm Blobel, Attorney-in-Fact For: Lan Xie 2017-10-16